Taysha Gene Therapies (TSHA) AGM 2026 summary

Opening remarks and agenda

• Meeting commenced virtually with introductions of board members, management, independent auditor, and legal counsel.

• Formal business followed the agenda outlined in the notice and proxy statement.

Board and executive committee updates

• Two Class III directors, Sean P. Nolan and Laura Sepp-Lorenzino, were nominated for election to serve until the 2029 annual meeting.

Shareholder proposals

• Four proposals were presented: election of directors, ratification of the independent auditor, advisory vote on executive compensation, and advisory vote on the frequency of future compensation votes.